Wall Street may or may not be going through its long-awaited correction these days, but regardless, it still seems to have a hearty appetite for digital health initial public offerings. That appetite is provoking venture capitalists to fund ever-more startups. Through June of this year, $2.3 billion has been sunk into digital health offerings compared with $2 billion in all of 2013, reports digital healthcare accelerator Rock Health.

“We think there's going to be four to five IPOs each year for the next five years.” said Steve Kraus, the lead healthcare partner at Bessemer Venture Partners, Cambridge, Mass.

As a small company, you have a number of things going for you because of your size: You're agile. You can react quickly to market changes. You can still innovate on a whim.

Big businesses know this all too well, which helps explain what's driving an increase in the number of corporate venture capital arms cropping up in the past few years. If the old chestnut is correct, a rising tide floats all boats. So as the economy recovers and some sectors like technology seem like they're heading toward irrational exuberance, corporate VC firms are eager to get in on the action. 

With an aging Baby Boomer population and broadband bandwidth improved a hundredfold from a decade ago, telemedicine is exploding as a convenient and less costly alternative to the traditional visit to the doctors' office.

This year in the U.S. and Canada, 75 million of 600 million appointments with general practitioners will involve electronic visits, or eVisits, according to new research from Deloitte.

In the August 18, 2014 issue of Forbes Magazine, the University of Maryland, College Park was ranked as one of the nation’s most entrepreneurial research universities. These rankings are based off of the number of alumni and students who have identified themselves as founders and business owners on LinkedIn against the school’s total student body which includes undergraduates and graduate combined.

Linda Wittbrodt was perusing Michigan Technological University’s website when she stumbled across a faculty project seeking funds to teach senior citizens online skills.

Wittbrodt thought that was cool, so she donated $25 through a new approach the Upper Peninsula university is using: pitching of an idea online and asking people to make a donation, a strategy known as crowdfunding.

The University of Maryland has launched an unmanned aircraft systems (UAS) test site in southern Maryland. With support from the University System of Maryland, the site will bring together leaders in academia, industry and government to accelerate UAS research.

Based in St. Mary’s County, a few miles from Naval Air Warfare Center Aviation Division at Patuxent River and the Naval Air Systems Command headquarters, the UMD UAS test site has been set up as a catalyst for research and development, according to its sponsors.

Anne Wojcicki bounds into a conference room in Mountain View, California, straight from a five-mile ride from home on an elliptical bike. The 40-year-old cofounder and CEO of the consumer genetic testing firm 23andMe is breathless, and not just because of the workout. On this warm day in mid-June, Wojcicki is “super-excited” about an announcement scheduled for two days hence: the Food and Drug Administration has agreed to review a health-related genetic report the company wants to make available to customers. 

ATCC, the premier global biological materials resource and standards organization, announced today that it has received ISO 13485:2003 certification for the development, manufacture, and distribution of standards, controls, reagents and in vitro diagnostic test kits.

Every day researchers in life science, medical diagnostics, applied sciences, and clinical drug development leverage ATCC’s expansive collection of cell lines, microorganisms, cellular and microbial panels, genomic and synthetic nucleic acids, biological products, and associated derivatives to generate quality research and reproducible results. ISO 13485 enhances ATCC’s existing Quality Management Program as an ISO 9001:2008 certified and ISO 17025:2005 and ISO Guide 34:2009 accredited organization.

IT deal flow remained steady in 2Q. About $17 billion of PE capital was invested through 89 transactions, with both figures in line with previous quarters. The software segment of the industry is particularly active, with 2014 on pace to surpass the annual deal flow totals of any year following the financial crisis. Software has become industry-agnostic in some respects, as everything from colleges to hospitals to industrial conglomerates have incorporated software solutions into their operating models. For PE investors, software providers offer strong recurring revenue streams and also boast greater add-on potential for platforms.

Rockville-based electronic prescription software service provider DrFirst on Wednesday announced $10 million in debt financing from Silicon Valley Bank.

The health IT company has expanded its products over the years to include software in medication management, adherence and care coordination. The company said the financing will go toward product development and an anticipated international expansion in the next year.

Emergent BioSolutions Inc. EBS -1.39% today announced that it has submitted a Biologics License Application to the U.S. Food and Drug Administration (FDA) for Anthrax Immune Globulin Intravenous (Human) [AIGIV] as part of a development contract with the Biomedical Advanced Research and Development Authority (BARDA). AIGIV, which was acquired in the Cangene acquisition completed earlier this year, is being developed as an intravenous therapeutic treatment for inhalation anthrax.

“This accomplishment is a testament to the diligent work of our employees within the recently acquired Cangene operations and their years of successful collaboration and partnering with the U.S. government,” said Adam Havey, executive vice president and president biodefense division at Emergent BioSolutions. “We commend BARDA for their steadfast commitment to advancing this key anthrax countermeasure program and remain dedicated to supporting their mission to protect our civilian and military population.”

Getting a shot is only a few seconds of discomfort, but that's the first line of defense against an infectious disease.

It's a process Emergent Biosolutions in Lansing knows well, as the only company that produces a licensed anthrax vaccine.

"Phase one is safety, phase two is selection and dose ranging, phase three we try to evaluate does it really work do we get the immune response we want," said President of the Biodefense Division at Emergent Adam Havey.

The National Center for Engineering Pathways to Innovation (Epicenter) is accepting proposals for its Pathways to Innovation Program.  

The Pathways to Innovation Program is designed to help institutions fully incorporate innovation and entrepreneurship into undergraduate engineering education. The program is run by Epicenter, which is funded by the National Science Foundation and directed by Stanford University and the National Collegiate Inventors and Innovators Alliance (NCIIA).

A study conducted by the Economic Alliance of Greater Baltimore Foundation (EAGB) to estimate Baltimore Gas and Electric’s (BGE) economic contributions to the region in 2013 found that its operations generated a total economic impact of $3.81 billion of output and supported 8,686 jobs. This resulted from the company’s direct effect, the effect of companies that provide services to BGE and the effect of employees of both BGE and the service companies.  BGE’s activities contribute more than 2 percent of the entire economic output of the BGE service area in central Maryland.

“We are proud to be able to support our partners in their goal of measuring and understanding their importance to the region’s workforce and economy,” said Tom Sadowski, President and CEO of the EAGB. “Our Chief Market Analyst, Patrick Dougherty, did a tremendous job of assessing and articulating the impact of BGE’s economic contributions to the region.”

Public health officials have just one tactic to battle the unrelenting Ebola virus outbreak in West Africa — quarantine — but as the disease continues to spread, scientists in Maryland are among those close to discovering other weapons.

Baltimore companies Profectus BioSciences and Paragon Bioservices, as well as researchers at the U.S. Army Medical Research Institute for Infectious Diseases at Fort Detrick in Frederick and the National Institutes of Health in Bethesda, have been part of efforts that have shown a handful of Ebola vaccine candidates are effective in monkeys.

A new collaboration between the USDA’s National Institute of Food and Agriculture (NIFA) Small Business Innovation Research Program (SBIR) and the USDA’s Agricultural Research Service (ARS) encourages SBIR applicants to license ARS technologies and be considered for a SBIR grant.

The relevant language in the SBIR’s “Request for Application” states: "Additional factors that will be considered in the review process include whether an application involves a CRADA with a USDA laboratory, or a license to a USDA technology, or is a resubmission. In the event that two or more applications are of approximately equal merit, the existence of a CRADA with a USDA laboratory or a license to a USDA technology will be an important consideration. If one application is a resubmission, this will also be an important consideration.” The SBIR Website can be found at: http://www.nifa.usda.gov/fo/sbir.

Accelerator Corporation, a US-based biotech investment and management company, has attracted a total of $51.1m for its Accelerator IV fund. The three major investors’ cash, Eli Lilly, Pfizer Venture Investments and Johnson & Johnson Development Corporation, make up $50m of the investment.

The three pharmaceutical companies and other existing investors Alexandria Venture Investments, WRF Capital and Arch Venture Partners, are joined by two new strategic investors. These are Harris & Harris, a venture capital firm, and The Partnership Fund for New York City, an evergreen fund by the city’s business and finance leaders.

Today, most healthcare organizations operate in ways that are antithetical to innovation. The trend in patient-centered healthcare is to focus on stability, predictability, standardization and the avoidance of risk. Process engineers are deployed to help hospitals and healthcare systems eliminate waste and improve their organizations using Lean and Six-Sigma principles. Few operators develop an effective focus on innovation. Therefore, few reap the rewards that innovative breakthroughs in patient care can bring.

In a recent Boston Consulting survey across different industries, 76% of executives ranked innovation as a “top-three” strategic priority for their company. Among CEOs specifically, that number rose to 85%, with nearly half of them ranking it as their #1 priority.

Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and re-generative medicine, today announced the appointment of industry veteran Scott Carmer as CEO of the company's North American subsidiary. Carmer has more than 25 years of diverse industry experience within both pharmaceutical and biotech companies. Orgenesis is a pioneer in the field of "cellular trans-differentiation," a technology that has potential to regenerate glucose-responsive insulin production and restore glycemic homeostasis for patients suffering from various insulin-dependent disorders. By transforming a patient's own liver cells into new insulin producing cells, Orgenesis hopes to develop a breakthrough therapy for people living with Type 1 Diabetes. In his new role, Carmer will oversee the Orgenesis drug development and commercialization strategy in North America, focusing on the near-term initiation of Phase I and Phase II clinical trials in the United States.

Aspiring entrepreneurs in Maryland have two great options for higher education, according to ranking website College Choice.

The University of Maryland, College Park snagged the No. 20 spot on website’s list of the 50 best U.S. colleges for entrepreneurs, while Johns Hopkins University came in a bit lower, at No. 36.

The latest outbreak of Ebola virus in west Africa is the worst ever—as of Monday, it had infected more than 1,200 people and claimed at least 672 victims since this spring. Guinea, Liberia and Sierra Leone all have confirmed cases. An official at Doctors Without Borders has declared the outbreak as “totally out of control,” according to NBC News. Unfortunately, doctors have no effective vaccines or therapies. Health care workers can only attempt to support patients’ immune systems (regulating fluids, oxygen levels, blood pressure and treating other infections) to help the afflicted fight off the virus as best they can.

Funding and Research Opportunities

The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:

NIH Guide Notices:

• Notice on Annual Reporting Requirements and Revised Financial Closeout Requirements for NIH Administrative Supplements Awarded to Recover Losses Due to Hurricane Sandy under the Disaster Relief Appropriations Act
  (NOT-OD-14-112) National Institutes of Health
• Notice of NHLBI Discontinuation of Grant Program "Ancillary Studies in Clinical Trials (R01)"
  (NOT-HL-14-232)National Heart, Lung, and Blood Institute
• Notice to Extend the Response Date for the NOT-HL-14-030 "Request for Information (RFI): NHLBI Whole Genome Sequencing Project (NHLBI-WGS)"
  (NOT-HL-14-233)National Heart, Lung, and Blood Institute

Program Announcements (PA):

• NHLBI Career Transition Award for Intramural Fellows (K22)
  (PAR-14-302)
  National Heart, Lung, and Blood Institute
  Application Receipt/Submission Date(s): Multiple dates, see announcement.

10 a.m. - 12 p.m. Saturday, Sept. 20

Join us for an open house to learn more about the Master of Liberal Arts program, which is expanding in January 2015 to the Montgomery County Campus. Classes will be available on evenings, Saturdays and online.

The Johns Hopkins Master of Liberal Arts (MLA) is a unique, non-traditional graduate degree. Whereas most graduate programs ask you to become more and more specialized, the MLA expects you to both broaden and deepen your educational experience. Established in 1962 and administered by the Center for Liberal Arts at Johns Hopkins University, the program has gained national recognition for the quality of its teaching and the breadth of its course offerings. The MLA thrives on the curiosity, passion and diversity of its students. Our community of scholars eagerly embraces the Master of Liberal Arts interdisciplinary approach and flexible curriculum to better understand more about the world—and in so doing, learn and understand more about themselves.

At the Sept. 20th open house, you will have the opportunity to meet the program directors and ask questions about the MLA degree.

The 2014 UEDA Awards of Excellence finalists have been chosen and the competition this year is at an all time high. Each year, universities and organizations across North America submit nominations for innovative programs that focus on developing economic prosperity in their communities and beyond. A panel university and economic development professionals have chosen 19 finalists from the group of nominated projects.

The UEDA awards are designed to help accelerate these programs by recognizing cutting edge initiatives, and to promote their adoption by other universities and communities. Program categories include: Community Connected Campuses, Innovation and Entrepreneurship, Leadership and Collaboration, Research and Analysis, Talent Development.

Opticul Diagnostics has won a BioMaryland Center grant to work on a medical device with a France-based company that would immediately identify microorganisms in a wound at a point-of-care setting, such as a hospital.

The device would be used on burn injuries and cutaneous wounds. The rapid identification of the bacteria in the wound would allow for quicker patient treatment.

Opitcul Diagnostics, based at Johns Hopkins University’s Montgomery County Campus, is collaborating with Diafir of Rennes, France. The two companies have received funding through a partnership between BioMaryland Center and Medicen Paris Region.

Image: http://mcc.jhu.edu

Montgomery County, MD DED Tech Transfer Programs Monthly Event - Second Wednesday of every month: 3:30 PM to 5:00 PM (EDT) Germantown, MD

Innovators and startups pride themselves on being creators of disruptive technologies. We expect them to introduce game-changing solutions that improve our quality of life and enable administrations to govern better.

But the journey from innovative solution to government adoption is far from easy and can seem impossible for smaller companies with cutting-edge technologies.

Image: http://www.statetechmagazine.com

Qiagen has agreed to partner with AstraZeneca to develop a liquid biopsy-based companion diagnostic test to accompany one of the pharmaceutical company's lung cancer drugs.

Building on a master framework agreement signed by both companies in 2013, the partnership will involve the creation of a diagnostic test that analyses plasma samples to assess EGFR mutation status in non-small cell lung cancer patients.

The healthcare system in the U.S. is a slow-moving, slow-changing beast, but it’s also riddled with inefficient parts that beg for data-driven reinvention. That’s created huge opportunities for startups — and some of them are already seeing the payoff. The Affordable Care Act and accompanying legislation like the HITECH Act have lit a fire under the movement to rethink they way we deliver and pay for healthcare. Accordingly, investment in the digital health space has accelerated in 2014; at the end of June it totaled $2.2 billion, already exceeding 2013’s total funding just halfway through the year.

According to the latest research out of Johns Hopkins, a new blood test could predict a person’s risk for suicide through their DNA. The blood test would rely on genetics and offer many who are afflicted with mental illness and their doctors a new option in detecting suicidal behavior.

Johns Hopkins researchers Aleksander Popel and Jordan Green knew their research could serve a greater purpose outside their laboratory. But without any business experience, they knew they couldn’t do it alone.

With help from Hopkins’ tech transfer office and the Maryland Innovation Initiative, a state grant fund that invests in research projects with commercialization promise, the pair’s biomedical research is now a company — AsclepiX Therapeutics. The company is developing a better way to treat eye conditions caused by blood vessel abnormalities. Macular edema, which is common among people with diabetes and can lead to blindness, is an example.

Image: Jaclyn Borowski - At left, Niranjan Pandey, senior director of research and development, and Eric Bressler, research specialist, work in the lab at AsclepiX Therapeutics. 

Report: “Safe Science: Promoting a Culture of Safety in Academic Chemical Research”

Author: Committee on Establishing and Promoting a Culture of Safety in Academic Laboratory Research

Organization: National Research Council

Summary: The National Research Council formed a panel of university lab-safety experts after a series of campus accidents, including several deaths, emphasized that academic labs have a far worse safety record than their corporate counterparts do.

Regardless of your stance on Obamacare and Maryland’s Medicare waiver, you can’t ignore that health reform and technology are creating many opportunities for innovation. The BBJ is looking for those innovators. Please click below for contest information.

For years the standard operating procedure for the medical device world has been: Bring good tech to patients and be rewarded by the market. Healthcare reform and particularly the consolidation of doctor practices is making this model obsolete. Now the challenge is more along the lines of “Justify your existence.”

Device companies have to revamp the traditional business model to show how their products save money and help patients in the long term.

Image: http://medcitynews.com 

Genome scientist and entrepreneur J. Craig Venter is best known for being the first person to sequence his own genome, back in 2001.

This year, he started a new company, Human Longevity, which intends to sequence one million human genomes by 2020, and ultimately offer Web-based programs to help people store and understand their genetic data (see “Microbes and Metabolites Fuel an Ambitious Aging Project”).

Image: http://www.technologyreview.com - J. Craig Venter